Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 408

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 408
---
 |    571,678 |   |     |      |       5,625 |   |
| Net decrease in cash, restricted cash, and cash equivalents     |     |      | (5,218,309 | ) |     |      | (12,397,918 | ) |
| Cash, restricted cash, and cash equivalents                     
 at beginning of year                                            |     |      |  6,819,564 |   |     |      |  19,217,482 |   |
| Cash, restricted cash, and cash equivalents                     
 at end of year                                                  |     | $    |  1,601,255 |   |     | $    |   6,819,564 |   |
| Supplemental disclosure of cash as reported within the audited  
 condensed balance sheets:                                       |     |      |            |   |     |      |             |   |
| Cash                                                            |     | $    |  1,518,676 |   |     | $    |   6,651,454 |   |
| Cash equivalents                                                |     |      |      2,823 |   |     |      |      88,354 |   |
| Restricted cash                                                 |     |      |     79,756 |   |     |      |      79,756 |   |
| Cash, cash equivalents, and restricted                          
 cash                                                            |     |      |  1,601,255 |   |     |      |   6,819,564 |   |

<div align='center'>See accompanying notes to financial statements.

F-54

CERo Therapeutics, Inc.

Notes to Financial Statements</div>

NOTE 1 – Organization and Description of the Business

Nature of Operations– CERo Therapeutics,
Inc. (the “Company”) was incorporated in Delaware on September 23, 2016, and is based in South San Francisco, California.
The Company is focused on genetically engineering human immune cells to fight cancer. Since inception, the Company has focused on developing
its therapeutic platform and has not yet begun clinical development or product commercialization. Future Company efforts will focus on
continued product development, including clinical development, to support regulatory approval to commercialize and subsequent product
commercialization.

Going concern– The accompanying
financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization
of assets and satisfaction of liabilities in the normal course of business. The Company’s